The use of granulocyte colony-stimulating factors (GCSFs) is a physiologic approach for the prevention of FN. It has been shown in a recent meta-analysis to reduce the relative risks of FN by 46%, infection-related mortality by 45% and early deaths by 40% [8] . In the pivotal placebocontrolled study by Crawford et al. [9], the incidence of confirmed infections was reduced by approximately 50% whenaG-CSFwasgiven.
The use of granulocyte colony-stimulating factors (GCSFs) is a physiologic approach for the prevention of FN. It has been shown in a recent meta-analysis to reduce the relative risks of FN by 46%, infection-related mortality by 45% and early deaths by 40% [8] . In the pivotal placebocontrolled study by Crawford et al. [9] , the incidence of confirmed infections was reduced by approximately 50% whenaG-CSFwasgiven.
Because G-CSFs are expensive, the criteria for their use have been based on purely economic grounds (i.e. cost savings),using,asthereference,thecostoftheinitialhospitalization for FN [2] . Although initially the threshold for recommending the prophylactic use of G-CSFs was a 40% risk of developing FN, presently most official guidelines, namely thoseproposedbytheEORTC(EuropeanOrganizationfor Research and Treatment of Cancer), recommend as the standardthresholda20%risk [10] .Accordingtothesestandards,patientswithlowerrisksofdevelopingFNafterchemotherapyarenoteligibleforprophylaxiswithG-CSFs,unless theyareolderthan65yearsand/orpresentseriousco-morbid conditions.
However,onceFNoccursthefrequencyofseverecomplicationsandtheriskofdeatharenotreducedinthosepatients having a risk of FN lower than 20% [11] . Thus the present recommendationsleaveaverylargepopulationofpatientsactuallythemajorityofsolidtumorpatientsreceivingstandard chemotherapy -with no protection against the consequences of FN, raising the question whether the indications for the use of G-CSFs for prevention of FN should not be extended [12] .
The paper by Ihbe-Heffinger in this issue of OnkOlOgie [13] ,raisesseveralinterestingquestionsregardingthecostof FNandactuallyprovidessomeresponsesabouthowtodeal with it. The authors evaluated 325 consecutive patients and focusedon58episodesofFNtoevaluatethecosts.Whilethe incidence reported for FN in their patients with lymphoma (22%) or aggressively treated breast cancer (27%) matches whatisusuallyreportedintheliterature [14, 15] ,itissurprising thatmostofthosepatientswithbreastcancerandlymphoma Febrile neutropenia (FN) is among the most frequent complicationsduringtheadministrationofcytotoxicchemotherapy. In spite of major progress in the management of FNduringthepastthreedecades,FNremainsassociatedwith a significant frequency (up to 30-40%) of serious complications and a non-negligible mortality (overall 5-10%) [1] . Besides the morbidity and mortality associated with FN, theexpensesresultingfromitsmanagementareconsiderable and, most likely, the figures presented in many studies are underestimated [2] . Asignificantimprovementtoreducehumansufferingand theeconomicalburdenofthemanagementofFNhasresulted fromthepossibilitytopredictaccuratelywhichpatientsareat arelativelylowrisk(>5%)ofdevelopingseriouscomplicationsduringFN [3] .Suchpatients,whorepresentatleast60% ofthewholepatientpopulationdevelopingFNafterchemotherapy, can be treated, in many cases, with orally administeredantibioticsandwithoutbeinghospitalizedforprolonged periodsoftime [4] .Thissimplifiedapproachhasbeenshown toreducetheexpensesresultingfromthemanagementofFN byabout45% [5] .Ofcourse,forthepatientswithapredicted higherriskofseverecomplicationsduringFN,hospitalization andempiricaltherapywithintravenouslyadministeredbroad spectrumantibioticsremainthestandardrules.Thesepatients willalsorequiremoreoftenintensivecaresupportandsome ofthemwilleventuallydiefromthecomplicationsofFN.This relativelysmallgroupofpatientswithcomplicatedFNisactuallyresponsibleforthemajorproportionofthecostsinvolved inthetreatmentofFN.
Themostobvioussolutionforsignificantlydecreasingthe morbidity and mortality resulting from FN, is prevention. EffectiveprophylaxisofFNmightalsoimpactonthecostsof managementofFN,dependingonhowexpensiveitwouldbe. The prophylactic administration of antibiotics, namely the fluoroquinolones, can significantly decrease the incidence of FNinpatientswithsolidtumors [6] orlymphomas [7] anditis verycheap.However,therisksassociatedwiththeinevitable emergence of resistance make many experts reluctant to recommendthisapproach. What can be done to extend the potential benefit of GCSFstopatientswitharelativelylowriskofFN?Somestudies, although retrospective, have suggested that, in patients with arelativelylowriskofFN,alimiteddosageofG-CSF(suchas 2 administrations, on days 8 and 12 after chemotherapy) mightbeeffective [16] .Ifweapplythatconcepttoourseries, asshownintable2,thecostoftheprimaryprophylaxiswould nowbe117,000€,whichisstillnotcosteffective,evenif50% of the patients with FN would be treated with ambulatory care(table1).Further,moreaffordableG-CSFs(theso-called biosimilars) are now available, reducing the cost of G-CSFs substantially (e.g. 300 mg Ratiograstim, Ratiopharm, Ulm, Germany, costs 106 €); this would further help with cost-effectiveness.
Thus,assummarizedintable2,areduceddosing(2injec-tions)withastandardG-CSF,wouldcost172,000€(notcosteffective) but, with a less expensive biosimilar, it would cost 68,900€,whichiscost-effective.Withthepossibilityoftreating asignificantproportionofthepatientsintheambulatorysetting,thisprophylacticapproach,combiningabiosimilarG-CSF andareduceddosagemightproveevenmorecostsaving.
As shown in table 2, we also calculated the minimum reduction of FN that would be required for G-CSF primary prophylaxis to be cost-effective with the different schedules proposed. Actually, the reduced dosage schedule would require a reduction of 60% of the incidence of FN with the standardG-CSFandonly35%withthebiosimilar.Ofcourse 'Papaldo'shypothesis' [16] needstobeconfirmedinprospectiveclinicalstudies,althoughincommonpractice,areduced dosingofG-CSFisalreadyusedempiricallybymanyoncologiststoday [17] .
In conclusion, the cost-analysis of FN by Ihbe-Heffinger providesanoutstandingopportunitytochallengeourpresent concepts for the prevention and management of FN in the future. Joined efforts between the clinical and industrial worlds should be encouraged to provide optimal protection against FN-associated morbid consequences in the vast majority of patients receiving chemotherapy for common neoplasticdiseases.
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didnotreceiveaprophylaxiswithG-CSFs,astheriskofFN was greater than 20%. It is also interesting to notice that 55 out of 58 episodes of FN were associated with at least one hospital stay, since hospitalization is no longer the standardformanypatientswithsolidtumorsexperiencingFN duringthecourseofstandardchemotherapy [4, 5] .Finally,as the cost of medical care varies from country to country, the data provided by Ihbe-Heffinger et al. [13] are very useful to show the average situation in Germany for 3 common malignancies. Overall, the results match what is published elsewhere [2] ,withthecaveatthatthesecostsmaybeunderestimated if the whole downstream neutropenia care is not fullytakenintoaccount.
The data allow, in addition, a speculative exercise about the cost effectiveness of G-CSF prophylaxis, would it have beengiventoallthepatientsinthisseries.
Actually, the mean cost of hospitalization, based on the author'sdata,was138,250€forlymphomas,32,643€forlung cancer and 25,578 € for breast cancer patients, totalizing 196,471 € (table 1). If we consider that G-CSF prophylaxis wouldhavebeeneffectiveinpreventing50%oftheepisodes of FN, the cost of management would then be 98,235 €. To theseexpensesshouldbeaddedthecostoftheG-CSF;ifthe sum would be inferior to the total cost of management reportedhere(196,471€),thestrategycouldbeconsideredas cost-effective.ThestandardcostofG-CSF(e.g.filgrastim)is 900 € for 5 administrations of 300 mg (price in Germany, 2011).Thismeansatotalcostofprophylaxisfor325patients, inthisseries,of292,500€;thismakesthussuchaprophylaxis noncosteffective,bystrictlyeconomicconsiderationsthatdo nottakeintoaccountthepotentialreductioninmorbidityand mortalityresultingfromtheuseofG-CSFs. 
